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USING MICRORNAS (MIRNAS) AS THERAPEUTIC AGENTS IN CANCER:  
TARGETING THE LINK BETWEEN THE DOWNREGULATION OF MIRNAS 
AND ONCOGENESIS 
AJAY S. NATHAN 
ABSTRACT 
With the worldwide prevalence of cancer, this disease has constituted a major 
public health problem for many years without great success in the development of 
treatment. This is due in part to the large genetic heterogeneity that exists, even between 
cancers of the same class. The current standard of care focuses on targeting shared 
elements such as rapid cell division, yet treatments like chemotherapy have tremendous 
cytotoxic and off-target adverse effects. Recently, a different link has been discovered 
that is shared by cancers of diverse types: the disruption in the regulation and expression 
of microRNAs (miRNAs). miRNAs, produced endogenously from discrete genes that 
exist for them, have been shown to be master regulators of diverse processes, including 
growth and division. They serve to downregulate or silence the expression of certain 
genes at the post-transcriptional level, with each miRNA regulating multiple target 
messenger RNAs. This provides an important therapeutic potential because the correction 
in the expression of any one miRNA, especially if it has tumor-suppressive functions, has 
the ability to inhibit cancer formation, growth, and metastasis by multiple related 
pathways.  
The mechanisms by which the expression of miRNA is altered in cancer are 
reciprocal; that is, the processes that lead to oncogenesis alter the production of miRNA 
  v 
and altered production of miRNA can lead to increased tumorigenicity. In particular, it 
has been found that miRNA is globally downregulated in most cancers. The 
downregulation of miRNA can arise incidentally because of chromosomal abnormalities 
that occur with cancer, or miRNA can be directly repressed through transcriptional 
control, epigenetic modification, or disruption in the biogenic production process. When 
miRNAs are downregulated, the condition can contribute to the main hallmarks of 
cancer: uncontrolled growth, angiogenesis, metastasis, and evasion of anti-growth and 
apoptotic signals.  
A therapeutic strategy that has been investigated in numerous preclinical studies 
is miRNA replacement therapy, and this treatment has been shown to be extremely 
efficacious with a wide range of candidates and targets in diverse cancer systems. 
However, these advances have only led to two clinical trials, partly because of the lack of 
efficacious delivery methods. Nevertheless, with the rapid advances being made in gene 
therapy to address these shortcomings, a translation of these benefits from the bench-to-
bedside is almost certain. 
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INTRODUCTION 
 
This thesis provides a review of microRNA (miRNA) and how its downregulation 
is involved in oncogenic pathways in order to judge the potential for using miRNA 
replacement as a treatment of cancer. Candidates with tumor-suppressive function 
validated through preclinical studies are discussed, as well as those that have progressed 
into clinical trials. Finally, future directions for artificially designed miRNA therapeutics 
in cancer are considered. The following introduction provides background information on 
the importance of research on new targeted drugs in this field, the biogenesis of miRNAs, 
and the mechanism of action of miRNAs.  
 
Importance of the Development of Molecular Targeted Cancer Therapies 
As one of the most common diseases, cancer places an extremely large burden on 
societies worldwide. There were 14.1 million new cases of cancer globally and 8.2 
million mortalities in 2012. These statistics are only expected to rise in the coming years 
because of the aging society and the growing environmental and lifestyle contributions to 
cancer (Torre et al., 2015). Thus, there is a continuing need for research and development 
of new treatments in this field.  
The current treatment of cancer is focused on a multidisciplinary treatment plan 
approached through a combination of major treatment methods such as surgery, radiation 
therapy, and chemotherapy (Chan, 2007). However, cytotoxic chemotherapeutic agents, 
which kill rapidly dividing cells, have many drawbacks (Sun et al., 2017). Their low 
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selectivity causes many adverse off-target effects and long-term health issues, and 
continued use has been associated with drug resistance and loss of efficacy.  
Oncogenesis is a multistep process involving the accumulation of multiple genetic 
abnormalities. Recent advances in the understanding of molecular mechanisms of these 
processes, such as the pathways that regulate cell growth, have ushered in a new era of 
targeted therapies (Schultz, 2005). Although no one therapy will be able to treat all types 
of cancer, the discovery of particular molecular mechanisms and signatures of cancer will 
aid in the development of novel therapies to specifically treat a patient’s cancer. The 
approval of targeted cancer therapies has soared in the last decade from being far lower 
than cytotoxic agents to being five times higher. Most of these agents are targeted against 
cell membranes or enzymes such as tyrosine kinase (Sun et al., 2017). With the rapid 
growth of the field of targeted cancer chemotherapies, the subcategory of gene therapy 
(treatment involving introduction of exogenous DNA or RNA) is emerging as well.  
The discovery of microRNAs (miRNAs) approximately 20 years ago and the 
ensuing research into their role in post-transcriptional gene regulation have caused a new 
excitement in the field of gene therapy. Subsequently, miRNAs have been linked to many 
cancers and thus could hold great promise as a therapeutic strategy in this disease. 
miRNAs are non-coding RNAs of about 22 nucleotides (nts) in length (Fabian, 
Sundermeier, & Sonenberg, 2010) that serve to regulate gene expression for a variety of 
pathways, including cell proliferation and cell death (Brennecke, Hipfner, Stark, Russell, 
& Cohen, 2003). Because miRNAs serve to regulate many processes, downregulation of 
their pathways can critically accelerate oncogenic transformation (Kumar, Lu, Mercer, 
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Golub, & Jacks, 2007). It has been shown that miRNA normally functions to prevent cell 
division and drive terminal differentiation. Thus downregulation of any one miRNA 
pathway can lead to stem cell-like growth, that is, continuing division without 
differentiation (Lu et al., 2005). In these cases, miRNA synthetically developed to mimic 
the endogenous miRNA (i.e., miRNA mimics) can be used to replenish the product of the 
downregulated pathway. This treatment, being investigated in numerous preclinical 
studies and a few clinical trials to date, shows potential as a curative treatment of these 
cancers. 
This thesis primarily evaluates and reviews developments in miRNA replacement 
therapy in which miRNA mimics are used to treat miRNA downregulation in cancers. 
Artificially designed miRNA also holds promise in another strategy for cancer 
therapeutics. Targeting specific genes can be difficult because many different types of 
genomic abnormalities accumulate in cancer cells and large genomic heterogeneity can 
exist even between cancers of the same class (The Cancer Genome Atlas Research 
Network, 2008). Since a single miRNA has the capability to silence multiple related 
genes, it has the potential to suppress the multiple oncogenic pathways that lead to cancer 
(Bader, Brown, Stoudemire, & Lammers, 2011).   
 
Biogenesis Endogenous miRNA  
Nuclear Processing 
Separate genes forming independent transcriptional units encode for miRNAs, 
although some miRNAs can derive from introns processed from genes that code for 
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proteins (Fabian et al., 2010). These genes are transcribed by RNA polymerase II (Y. Lee 
et al., 2004) or RNA polymerase III (Borchert, Lanier, & Davidson, 2006) to produce 
long hairpin-loop primary miRNA (pri-miRNA) transcripts that are processed in the 
nucleus by a multifunctional enzyme complex termed the microprocessor. The 
microprocessor consists of two components: the ribonuclease III (RNase III) 
endonuclease Drosha and the protein DiGeorge syndrome critical region 8 (DGCR8) that 
binds double-stranded (ds) pri-miRNA (R. I. Gregory et al., 2004). The pri-miRNA is 
cleaved at the 5ʹ and 3ʹ ends by the microprocessor to form the 60-70-nt precursor 
miRNA (pre-miRNA), which then folds into a stem-loop hairpin structure. This is 
exported into the cytoplasm by means of exportin-5 (Lund, Güttinger, Calado, Dahlberg, 
& Kutay, 2004) in the presence of the Ran-guanosine triphosphate (GTP) cofactor (Yi, 
Qin, Macara, & Cullen, 2003).  
Cytoplasmic Processing 
Once in the cytoplasm, pre-miRNA is further processed by Dicer, another RNase 
III enzyme that functions as a part of the RNA-induced silencing complex (RISC)-
loading complex. The RISC-loading complex also contains a double-stranded RNA 
(dsRNA)-binding protein called transactivation-responsive RNA-binding protein 
(TRBP), a protein activator of protein kinase R (PKR), and Argonaute (Ago) proteins. 
Not only are Ago proteins involved in the loading process, but Ago2 is particularly 
important in strand selection and for later post-transcriptional regulation. Dicer cleaves 
the loop portion of the pre-miRNA and forms 22-nt ds miRNA. The ds miRNA is 
unwound by various helicases, and the accessory proteins dissociate from the RISC-
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loading complex. This leads to the formation of the miRNA-induced silencing complex 
(miRISC), which contains a single strand of guide miRNA (Fabian et al., 2010). The 
complete process is illustrated in Figure 1.  
 
Figure 1. Nuclear and cytoplasmic events in miRNA biogenesis. miRNAs are 
transcribed from genes by RNA polymerase II or III to form pri-miRNA in the nucleus, 
which is processed by Drosha, a type III RNase, to form pre-miRNA. Exportin-5/Ran-
GTP transports pre-miRNA by means of nuclear pores to the cytoplasm, where it is 
further processed by Dicer. Single-stranded mature miRNA is loaded onto RISC and used 
as a guide for translation repression and mRNA degradation. Ago2 = Argonaute 2; 
DGCR8 = DiGeorge syndrome critical region 8; GTP = guanosine triphosphate; miRNA 
= microRNA; mRNA = messenger RNA; pol = polymerase; pre-miRNA = precursor 
microRNA; pri-miRNA = primary microRNA; RISC = RNA-induced silencing complex; 
RNase = ribonuclease; TRBP = transactivation-responsive RNA-binding protein. Figure 
taken from (Fabian et al., 2010).  
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The Mechanism of Action of miRNA 
There are two ways in which miRNA acts to limit gene expression: by degrading 
or destabilizing messenger RNA (mRNA) or by directly disrupting the process of 
translation. There are no sequences of miRNA that are fully complementary to a human 
gene, and thus the pathway of post-transcriptional gene repression is determined through 
imperfect binding with and the degree of complementarity in key sites between the guide 
miRNA and the mRNA (Hutvágner & Zamore, 2002). These two methods of miRNA 
control are not mutually exclusive but rather can act simultaneously through distinct 
mechanisms of action (Fabian et al., 2010). The extent to which each mechanism plays a 
role is dependent on the system and is highly controversial. Nevertheless, there is some 
evidence to show that translation repression is the more central mechanism and occurs 
temporally before mRNA degradation (Bazzini, Lee, & Giraldez, 2012).  
Translational Repression 
Translation is a multistep process requiring many cofactors, and it can be divided 
into three main stages of initiation, elongation, and termination. miRNA can block 
translation at either the initiation stage or some stage after initiation (Fabian et al., 2010). 
However, in general, the mechanisms presented focus on regulation at the initiation stage 
because it is the most upstream process and appears to be the most common method of 
repression. Thus, the following paragraph provides a brief description of this stage with 
the details pertinent to this discussion.  
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Translation Initiation. Prior to translation initiation, protein-coding genes are 
transcribed in the nucleus into mRNA. The mRNA is modified post-transcriptionally to 
add a 7-methylguanosine triphosphate cap (in addition to 3ʹ polyadenylation and intron 
splicing) that protects it and allows for translation initiation. Translation occurs in the 
cytoplasm, and cap-dependent initiation begins with the recruitment of required 
eukaryotic initiation factors (eIFs). These eIFs form a multifunctional complex that 
associates with the cap, and the complex then recruits the small ribosome subunit to 
associate with mRNA near the 5ʹ cap. This complex travels in the 5ʹ to 3ʹ direction 
scanning for the start codon contained in the Kozak sequence. The 3ʹ polyadenylated 
[poly(A)] tail associates with a poly(A)-binding protein (PABP) and the eIF complex to 
enhance translation initiation, forming a loop-like structure in the mRNA. After the 
Kozak sequence is reached, GTP is hydrolyzed with another eIF, the large subunit 
associates, and elongation of the polypeptide can occur (Fabian et al., 2010). 
There are many studies to show that translation inhibition occurs at the initiation 
step. For example, if eIF factors are mutated, the translation inhibition by way of miRNA 
is antagonized (Mathonnet et al., 2007). This leads to the conclusion that early steps, such 
as eIF interaction with the mRNA cap, are points of translation initiation repressed by 
miRNA. It has also been suggested that miRNAs can impede the formation of the loop-
like structure in mRNA, which would cause a weaker association between eIFs and the 
cap (Fabian et al., 2010). The mechanisms by which miRNAs inhibit translation are not 
fully understood, especially in humans. However, these examples provide some idea of 
 8 
how miRNAs can disrupt the process of translation and lead to post-transcriptional gene 
regulation.  
mRNA Destabilization  
Although miRNA disrupts the process of translation, mRNA destabilization also 
plays a major role in the downregulation of genes. In one study, it was found that even 
though translation was inhibited, there was a 50% decrease in the amount of target RNA 
(Petersen, Bordeleau, Pelletier, & Sharp, 2006). There are many proposed mechanisms 
for the observed mRNA repression. One study has suggested that miRNA functions 
through deadenylating the poly(A) tail (Giraldez et al., 2006). The poly(A) tail provides 
stability to the mRNA, and when the poly(A) tail is removed, mRNA decay is enhanced. 
The poly(A) tail, as discussed in the previous section, is also involved with translation 
initiation and thus could function in this way to repress translation initiation. However, 
deadenylation directly mediated by miRNA is more responsible for target mRNA 
degradation than translation repression alone (Giraldez et al., 2006). Indeed, it has been 
shown that there is significant miRNA-mediated mRNA degradation even in the presence 
of translation inhibitors (Eulalio et al., 2007), which strongly suggests that an 
independent mechanism for mRNA degradation exists. 
Central to the process of direct degradation of mRNA is Ago2. miRNA is known 
to contain “seed” regions that are used for target recognition and complementarity (Lai, 
Tam, & Rubin, 2005). When an mRNA is sufficiently complementary to the miRNA seed 
sequence, it can be directly cleaved by the endonuclease activity of Ago2 (Liu et al., 
2004). However, in humans, this level of complementarity is rare, and thus another 
 9 
mechanism of mRNA degradation could play a more central role. There are portions in 
the cytoplasm known as processing bodies (P-bodies) which contain mRNA degradation 
enzymes. There is evidence to show that Ago proteins colocalize with mRNA targets to 
these P-bodies to stimulate mRNA degradation (Meister et al., 2005). P-bodies also 
contain the carbon catabolite-repression 4-Not (CCR4-NOT) complex which 
deadenylates mRNAs, decapping factors, and other translational repressors that could all 
serve to destabilize or impede the functioning of mRNAs (Behm-Ansmant et al., 2006).  
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Objectives 
This thesis aims to: 
1. Review the reciprocal mechanisms by which downregulated miRNA is linked to 
oncogenesis.   
2. Provide an overview of downregulated miRNAs in cancers and a general survey 
of the current miRNA replacement therapy field in preclinical studies. 
3. Assess the challenges and strategies involved with using miRNA mimics as 
therapeutic agents, discuss the potential targets, and evaluate the efficacy of those 
mimics that have progressed to clinical trials. 
4. Discuss the potential use of miRNA therapeutic agents for gene silencing and 
conclude with future directions of miRNAs in cancer therapeutics. 
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MECHANISMS OF miRNA DOWNREGULATION IN CANCER 
 
Certain miRNAs are upregulated in some cancers, and in these cases, they are 
termed onco-miRNAs in that they promote oncogenesis. However, cancer is generally 
associated with loss of function of miRNA regulation. When diverse cancers were 
profiled, miRNA expression was found to be globally downregulated (Lu et al., 2005). 
There are many mechanisms by which miRNA can be downregulated in cancer. The 
following sections are a review of the ways in which miRNAs can become 
downregulated in the process of oncogenesis.  
 
Incidental Reduction Due to Chromosomal Position 
The genes for miRNAs are located in fragile areas of DNA, or breakpoints, and 
these positions make them susceptible to loss through DNA damage (Calin et al., 2004). 
As a consequence of the deleted regions and deleted miRNA genes, reduced miRNA 
expression has been reported. In a genome-wide association study of breast cancer, 
ovarian cancer, and melanoma, it was found that there were a high number of miRNA 
copy number alterations in these cancers and that the alteration of miRNA genes was an 
important part of miRNA dysregulation and oncogenesis (Zhang et al., 2006). Even at the 
genomic level of a diverse range of cancers, the strong association between miRNA copy 
number alterations and the development of cancer has been linked.  
Although certain miRNA downregulations are common to many different cancers, 
each type is expected to have a signature in the copy number and expression levels of a 
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specific miRNA (Zhang et al., 2006). For example, evidence can be used from one 
genotypic study performed on 60 patient samples with chronic lymphocytic leukemia 
(CLL). CLL, the most common adult leukemia, results from hemizygous or homozygous 
chromosomal loss at 13q14 in more than half of the subtypes and is often the only genetic 
aberration. It can be inferred that genes in this location contain some tumor suppressor 
function. In this region, miRNA-15 and miRNA-16, two miRNA genes, were found to be 
deleted as well, and on evaluation of the expression levels, they were found to be low in 
68% of the CLL patients (Calin et al., 2002). Thus, it is clear that there is a link between 
the genetic abnormalities that cause oncogenesis and the expression of miRNA.  
 
Dysregulation of Transcriptional Control 
 The expression of miRNA is regulated through transcription factors, and certain 
malignancies can directly interfere with the normal function of transcription factors, 
reducing transcription of miRNA genes. This mechanism is increasingly being linked to 
the development of disease (Mraz, Pospisilova, Malinova, Slapak, & Mayer, 2009). One 
mechanism that has been proposed is direct binding to the promoter elements of the 
miRNA genes. A well-documented example is c-myc, which is classified as a proto-
oncogene. A proto-oncogene is a normal gene that, when mutated, contributes to the 
development of cancer. Its gene product, c-Myc, is a transcription factor that regulates the 
cell cycle, apoptosis, growth, and metabolism. When c-Myc is overexpressed, it can drive 
proliferation; thus, it is considered a hallmark of many cancers (Dang et al., 1999).  
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The miRNA-17 cluster has been identified as the target of c-Myc. In malignancies 
in which c-Myc is activated, 6 miRNAs of this cluster are activated as well. The 
downstream effect of c-Myc is E2F1 activation, which drives progression of the cell 
cycle (O’Donnell, Wentzel, Zeller, Dang, & Mendell, 2005). Although c-Myc activates 
oncogenic miRNAs, only two of them show statistically significant overexpression. It 
was found that c-Myc more significantly represses a diverse group of tumor-suppressive 
miRNAs. These include miRNA-15a, miRNA-22, miRNA-26, miRNA-29, miRNA-30, 
and lethal (let)-7 families. There is evidence to show that c-Myc directly binds to sites 
upstream of the gene on the 5ʹ end of the pri-miRNA. This provides verification that c-
Myc binds to promoters for these miRNA genes and inhibits them, thus repressing their 
transcription (Chang, Yu, et al., 2007). An example of this mechanism of promoter 
repression occurs in hepatocellular cancer, in which c-Myc directly represses miRNA-
122. However, in this case, c-Myc also functions to suppress the endogenous 
transcription factor of miRNA-122. Finally, c-Myc is reciprocally repressed through 
miRNA-122. The disruption of this pathway is the critical aspect of the oncogenic 
pathway of hepatocellular carcinoma (Wang et al., 2014).  
Another important transcription factor that is involved with cancer is p53, a 
protein which controls the cell cycle, differentiation, DNA repair, and apoptosis (Olivier, 
Petitjean, Fromentel, & Hainaut, 2010). p53 is encoded by the tumor suppressor gene 
TP53, which is considered to be a gene of essential importance that, when mutated, leads 
to oncogenesis. Loss of function of the p53 transcription factor leads to release from 
replication inhibition under times of cellular stress, and with reduced ability for DNA 
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repair, cells accumulate mutations that result in cancer. In fact, mutations in TP53 are the 
most common alterations across all cancer types (Olivier et al., 2010). One example of its 
association with miRNA regulation is the p53-miRNA-34 regulatory axis. The miRNA-
34 gene is found to be deleted in many cancers. The p53 transcription factor directly 
induces the transcription of the miRNA-34 family by means of the previously described 
mechanisms to yield some of the tumor-suppressive effects, such as cell-cycle arrest and 
apoptosis (Chang, Wentzel, et al., 2007). In other studies, p53 has been similarly shown 
to induce the production of miRNA-605 (Xiao, Lin, Luo, Luo, & Wang, 2011), miRNA-
1246 (Zhang, Liao, Zeng, & Lu, 2011), and miRNA-107 (Yamakuchi et al., 2010). 
In summary, oncogenic proteins can directly repress miRNA production, which 
drives the cell toward cancer, especially when the repressed miRNAs have tumor-
suppressive functions.  
 
Dysregulation in Epigenetic Modifications 
Epigenetic modifications are a hallmark of cancer and can be used to distinguish 
between normal and cancerous cells. A large amount of hypomethylation is one such 
epigenetic feature that is found in cancer (Feinberg & Vogelstein, 1983). The presence of 
hypomethylation on oncogenes increases their level of transcription. Tumor suppressor 
genes can also be silenced by hypermethylation on the 5ʹ regulatory region of genes 
(Herman et al., 1994). Methylation as a regulatory mechanism appears to only play a role 
in a minor portion of overall miRNA regulation (about 10% in a model of colon cancer). 
However, for those miRNAs controlled through DNA methylation, this method of 
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regulation has a major effect on the expression of miRNA (Han, Witmer, Casey, Valle, & 
Sukumar, 2007).  
An example of this process is illustrated in acute myelogenous leukemia. 
Resulting from a chromosomal translocation, the most common fusion protein, acute 
myelogenous leukemia 1 (AML1)/eight twenty-one (ETO), is formed. This protein 
directly targets miRNA-223; however, rather than inhibiting its transcription, it recruits 
chromatin remodeling enzymes to induce heterochromatic silencing (Fazi et al., 2007). 
The mechanism for silencing is as follows: (1) AML1/ETO fusion protein recruits a 
combination of histone deacetylases (HDACs), which allow histones to associate more 
tightly with DNA and repress transcription, and DNA methyltransferases (DNMTs) (S. 
Liu et al., 2005). (2) DNMTs methylate the cytosines on “CpG islands,” sites of 
transcription regulation located upstream of the gene, in which a cytosine is followed by 
a guanine in the linear sequence of bases. (3) DNA methyl-CpG-binding proteins 
associate with methylated CpGs, inhibit transcription through repressors, and modulate 
chromatin remodeling (Ng et al., 1999). Expression levels of miRNA-223 can be restored 
with a demethylating treatment that allows the cell to return to normal cycles of 
replication and differentiation (Fazi et al., 2007). 
Expression of 17 out of 313 human miRNAs is greatly upregulated in the 
presence of demethylating agents or HDAC inhibitors in transitional carcinoma cells 
compared with normal cells (Saito et al., 2006). In particular, miRNA-127 is located 
within a CpG island and is expected to be highly regulated by epigenetic modifications. 
The expression of miRNA-127 is silenced in human cancer cells. Indeed, miRNA-127 
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was found to be downregulated in tumors of the bladder, prostate, and colon, whereas it 
was highly expressed in the corresponding normal tissue (Saito et al., 2006). One target 
of miRNA-127 is the proto-oncogene B-cell lymphoma 6 (BCL6), and thus 
downregulation of the miRNA releases the inhibition on expression of BCL6, which 
contributes to oncogenesis. Upon introduction of exogenous miRNA-127, it was found 
that BCL6 was inhibited, indicating that a potential treatment of this nature could be 
efficacious in therapy (Saito et al., 2006). Similarly, the effect of a DNA-demethylating 
agent on miRNA expression was tested in lymph node metastatic cancer cells (Lujambio 
et al., 2008). The miRNAs found to be upregulated following this treatment were 
miRNA-148a, miRNA-34b/c, and miRNA-9, which are known to undergo 
hypermethylation-related silencing in cancer. Most important, this study found that 
restoration of expression of these miRNAs could be efficacious in inhibiting metastasis 
(Lujambio et al., 2008).  
Other studies have elucidated cancers in which epigenetic inactivation leads to 
downregulated miRNA. In breast cancer, there is epigenetic silencing of miRNA-9 
(Lehmann et al., 2007), and in lung (Donzelli et al., 2015) and colon cancers (Wang et 
al., 2016), miRNA 145-5p is silenced. These studies illustrate that epigenetic 
transcription repression is a major mechanism in miRNA downregulation in cancer and 
thus could be an important factor in the development of future therapies.  
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Dysfunction in miRNA Biogenesis  
 As previously described, miRNA biogenesis is a complex process involving a 
number of steps and enzymes. Cancer can involve the mutation or the repression of 
function of any of the involved enzymes or transporters, leading to reduced production of 
miRNA. In some cases, miRNA downregulation in cancer can occur during the miRNA 
processing inhibition at the Drosha step, where pri-miRNA is cleaved (Thomson et al., 
2006). In an analysis of Wilms tumors, 15% displayed mutations in DGCR8 and Drosha 
that resulted in decreased expression of let-7a and the microRNA (miR)-200 family of 
miRNAs (Walz et al., 2015). Dicer was found to be impaired in colorectal cancer, and the 
resulting low miRNA levels contributed to an enhanced tumor stem-like nature and 
metastatic potential (Iliou et al., 2013). These dysfunctions in miRNA biogenesis 
enzymes have direct correlation with patient outcomes. In an analysis of 111 specimens 
from patients with invasive epithelial ovarian cancer, the levels of Dicer and Drosha were 
found to be decreased in over half the samples. Low Dicer levels significantly correlated 
with advanced tumor stages. Higher levels of both enzymes significantly correlated with 
increased survival (Merritt et al., 2008). Similar correlations were found in a study 
conducted on patients with lung cancer (Karube et al., 2005).  
Cancer can disrupt miRNA biogenesis at the cytoplasmic stages involving RISC. 
In particular, the expression of Ago proteins, essential to the functioning of RISC, can be 
downregulated. In melanoma, Ago2 expression was found to be greatly reduced by 
means of post-transcriptional regulatory methods (Völler, Reinders, Meister, & 
Bosserhoff, 2013). Another step in the miRNA biogenesis machinery that can be affected 
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is exportin-5. This transporter mediates pre-miRNA export from the nucleus and can be 
inactivated because of genetic mutation in some types of cancer. A defect in exportin-5 
would block pre-miRNAs in the nucleus, decreasing miRNA processing and therefore 
miRNA-mediated silencing (Melo et al., 2010). 
All of the known changes in miRNA biogenesis leading to cancer are illustrated 
in Figure 2. These studies show that oncogenic processes can downregulate miRNA by 
impairment in the mechanisms of its biogenesis, and these processes have direct effects 
on the prognosis and severity of cancers (Merritt et al., 2008).  
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Figure 2. miRNA biogenesis and links to cancer. Defects in any step of the process in 
miRNA biogenesis can lead to decreased miRNA production. As shown in the figure, 
certain mutations and decreases in miRNA have been linked to cancer. Ago = Argonaute; 
CLL = chronic lymphocytic leukemia; DGCR8 = DiGeorge syndrome critical region 8; 
GTP = guanosine triphosphate; let = lethal; miR = microRNA; miRNA = microRNA; 
mRNA = messenger RNA; pol = polymerase; pre-miRNA = precursor miRNA; pri-
miRNA = primary miRNA; RISC = RNA-induced silencing complex; TRBP = 
transactivation-responsive RNA-binding protein. Figure modified from (Rupaimoole & 
Slack, 2017).  
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MECHANISMS OF ONCOGENESIS FROM DOWNREGULATED miRNA  
 
Hanahan and Weinberg (2000) set the currently accepted standard of six 
hallmarks that characterize the development of cancer. These features are: (1) self-
sufficiency in growth signals, (2) evading apoptosis, (3) insensitivity to anti-growth 
signals, (4) tissue invasion and metastasis, (5) limitless replicative potential, and (6) 
sustained angiogenesis (Hanahan & Weinberg, 2000). The downregulation of miRNA 
can contribute to oncogenesis in each of these six ways. This section provides examples 
of how miRNAs can contribute to these hallmarks of cancer in order to understand how 
the reversal of downregulation or the repletion of these miRNAs can be used in 
treatment. 
 
Uncontrolled Growth: Self-Sufficiency in Growth Signals 
There are several signaling pathways involved with growth, proliferation, and 
differentiation that are regulated by miRNAs. Certain miRNAs involved with signaling 
pathways are upregulated in cancer, such as the previously described miRNA-17 cluster 
induction of E2F1 expression and the miRNA-221/222 targeting and downregulating of 
the expression of cyclin-dependent kinase (CDK) inhibitors (Gillies & Lorimer, 2007). 
Both of these miRNA upregulations drive the cell toward replication. However, one 
pathway that is involved with downregulated miRNA is the insulin-like growth factor 
(IGF) pathway. This pathway is engaged with normal growth and development, but its 
dysfunction is implicated with several disease states. The IGF pathway is mediated by 
 21 
IGF-I and IGF-II, two proteins which activate separate receptors and downstream 
messengers. The downstream effects of IGF-I are especially important for its implication 
in oncogenesis. IGF-I binds to its receptor (IGF-IR, a receptor tyrosine kinase), which 
shares structural homology to the insulin receptor. Therefore, the signaling pathways for 
these messengers overlap to some extent. IGF-IR activates two signaling cascades: 
phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK). The 
PI3K and MAPK pathways are illustrated as an overview in Figure 3. The following 
description of these pathways has been adapted from the work of Ferguson and 
colleagues (2012). 
In the PI3K pathway, there is recruitment of insulin receptor substrates that 
associate with PI3K and activate it. Once PI3K is activated, phospholipid 
phosphatidylinositol 3,4,5-trisphosphate in the plasma membrane increases, leading to the 
activation of protein kinase B (Akt) and its association with the membrane. Akt proceeds 
to activate several downstream effectors involved with metabolism, survival, migration, 
and proliferation. One important effector is the mammalian target of rapamycin (mTOR) 
complex 1, which induces growth, metabolism, and the production of protein by 
activation of an eIF. Akt also inactivates the cell-cycle arrest by promoting forkhead box 
O (FOXO) transcription factors and the apoptotic protein Bcl-2-associated death 
promoter (BAD). The inactivation of the glycogen synthase kinase 3 (GSK3) leads to 
anti-apoptotic and hypertrophic effects (Ferguson et al., 2012). 
In the MAPK pathway, the guanine nucleotide exchange factor son of sevenless 
(SOS) is recruited to activate the GTPase, which activates the MAPK kinase kinase RAF. 
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RAF phosphorylates the MAPK kinase MEK, which then phosphorylates MAPK. 
Phosphorylated MAPK becomes activated to perform its downstream actions. Two 
important MAPK effectors are the extracellular signal-regulated kinase (ERK) and the 
p38 MAPK, which promote mitosis and inflammation. This pathway is involved in the 
migratory ability of the cell, and its overactivation contributes to immunity (Ferguson et 
al., 2012). 
 
 
Figure 3. Overview of the downstream effects of IGF-IR. The binding of IGF-I to its 
receptor IGF-IR leads to two primary pathways—PI3K and MAPK. The diverse effects 
of IGF-IR activation include increased metabolism, proliferative ability, survival, 
migratory ability, and hypertrophy. Overactivation of these pathways is implicated in 
oncogenesis. Akt = protein kinase B; BAD = Bcl-2-associated death promoter; ERK = 
extracellular signal-regulated kinase; FOXO1 = forkhead box O1; GSK3 = glycogen 
synthase kinase 3; IGF-I = insulin-like growth factor-I; IGF-IR = insulin-like growth 
factor-I receptor; MAPK = mitogen-activated protein kinase; mTOR = mammalian target 
of rapamycin; PI3K = phosphoinositide 3-kinase. Figure modified from (Ferguson et al., 
2012). 
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Non-small cell lung cancer is one of the disease states implicated with a 
dysregulated IGF-I pathway. In non-small cell lung cancers, miRNA-486 was found to be 
the most downregulated miRNA compared with miRNAs in other lung tissues (Peng et 
al., 2013). It was determined that the target of miRNA-486 was IGF-I. Since IGF 
activates separate pathways that affect cell survival and growth, overactivation of this 
growth factor, because of its loss of regulation by miRNA-486, could provide continuous 
stimulation of these proliferative pathways. Most important, when miRNA-486 was 
administered to non-small cell lung cancer cell lines, growth and migration were 
inhibited (Peng et al., 2013). 
 
Evasion of Apoptotic Signals 
The evasion of apoptosis allows tumors to progress without the normal signals 
that cause cell death upon the accumulation of mutations which could lead to 
oncogenesis. Proteins of the caspase family are the primary mediators of apoptosis, and 
they function as part of signaling cascades that amplify signals of apoptosis to lead to cell 
death. There are two pathways by which a cell can undergo apoptosis: (1) the intrinsic 
pathway or (2) the extrinsic pathway (Vaux, 2014). These two pathways are illustrated in 
Figure 4 and are briefly summarized in the following description with details pertinent to 
this discussion.  
1. In the intrinsic pathway, the mitochondria are primarily involved through the 
creation of the apoptosome. Cell damage and normal processes such as 
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developmental cues or lack of stimulation by growth factors can lead to activation 
of this pathway, which damages the mitochondria. The Bcl-2 family is the 
primary mediator of this pathway and consists of both pro-apoptotic and anti-
apoptotic proteins. If the balance of these proteins is shifted in the apoptotic 
direction, then cytochrome c is released, and the apoptosome forms around the 
apoptotic protease-activating factor 1 (Apaf-1) protein. This process results in 
caspase-9 activation, which then activates caspase-3/7 and causes cell death 
(Vucic, 2014). 
2. The death receptor (DR) family mediates signal transduction in the extrinsic 
pathway. This pathway is initiated when tumor necrosis factor (TNF) ligands bind 
tumor necrosis factor receptors (TNFRs). The binding of the ligands causes 
TNFRs to aggregate and recruit the death-inducing signaling complex (DISC). 
DRs and the first apoptosis signal (Fas) then associate with the Fas-associated 
protein with death domain (FADD) which activates caspases intracellularly. 
Caspase-8 activation triggers caspase-3/7 activation, leading to cell death. The 
TNFR recruits additional proteins to activate caspase-8 through the TNFR type 1-
associated death domain (TRADD) and its accessory proteins [TNFR-associated 
factor 2 (TRAF2), c-inhibitor of apoptosis (c-IAP), and receptor-interacting 
protein 1 (RIP1)]. These proteins can also directly stimulate cell death by means 
of necroptotic pathways (Vucic, 2014).  
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Figure 4. Intrinsic and extrinsic pathways of apoptosis. The intrinsic pathway 
involves mitochondrial release of cytochrome c, whereas the extrinsic pathway involves 
death receptors. Both pathways converge on the activation of caspase-3/7 to trigger 
apoptosis. Bcl = B-cell lymphoma; FADD = Fas-associated protein with death domain; 
Fas = first apoptosis signal; FLIP = FLICE-like inhibitory protein; IAP = inhibitor of 
apoptosis; MLKL = mixed lineage kinase domain-like; PGAM5 = phosphoglycerate 
mutase family member 5; RIP = receptor-interacting protein; TRADD = TNFR type 1-
associated death domain; TRAF2 = TNFR-associated factor 2; TRAIL = TNF-related 
apoptosis-inducing ligand; TNF = tumor necrosis factor; TNF-R = tumor necrosis factor 
receptor (TNFR). Figure taken from (Vucic, 2014).  
 
Apoptosis is partially controlled by p53, which is a tumor suppressor transcription 
factor that was described previously. There are two pathways that can be activated by p53 
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when DNA damage is sensed: (1) cell-cycle arrest and activation of DNA repair 
machinery or (2) apoptosis by either of the two pathways to prevent proliferation of 
potentially malignant damaged cells if the damage is unrepairable (Redondo, Fùnez, & 
Esteban, 2009). Thus, when the functions of p53 are antagonized, cancer is able to 
progress beyond the control mechanisms of programmed cell death. One such way of 
accomplishing this is with murine double minute 2 (MDM2), a protein that degrades p53. 
As a transcription factor, p53 induces the production of certain miRNAs which are 
responsible for the tumor-suppressing effects of p53. In a study of multiple myeloma, a 
B-cell neoplasm, it was found that miRNA-192, miRNA-194, and miRNA-215, which 
function to suppress the expression of MDM2, were epigenetically downregulated. This 
leads to low levels of p53 and subsequent suppression of its anti-apoptotic functions 
(Pichiorri et al., 2010).  
Another important regulator of apoptosis is the Bcl-2 protein family. Bcl-2 is an 
anti-apoptotic factor that is often overexpressed in cancer and is critically involved in the 
intrinsic pathway of apoptosis. For example, in the previously discussed case of CLL, 
which is caused by a deletion in miRNA-15 and miRNA-16, it was found that the mRNA 
for Bcl-2 is a target for these miRNAs (Cimmino et al., 2005). Thus, with the low levels 
of these miRNAs in CLL, cancerous cells are able to evade apoptosis because of the lack 
of negative regulation on the anti-apoptotic factor Bcl-2. Most important, when miRNA-
15 and miRNA-16 were re-introduced into the CLL cell line, they caused apoptosis by 
means of Bcl-2 repression (Cimmino et al., 2005). Similarly, miRNA-365 (Nie et al., 
 27 
2012), miRNA-204 (Sacconi et al., 2012), and miRNA-148a (H. Zhang et al., 2011) have 
all been found to regulate Bcl-2 in this way.  
 
Tissue Invasion and Metastasis 
The action of epithelial-to-mesenchymal transition (EMT) is a normal process 
involved in fetal development and wound healing. In this process, epithelial cells lose 
their lateral adhesion and are able to move and transform into mesenchymal cells. 
However, the same mechanisms involved with this process are implicated in malignant 
cancer progression and metastasis (Roche, 2018). In addition, the EMT process is in a 
transitional state in cancer, possessing both epithelial and mesenchymal phenotypes. This 
condition gives cancerous cells more aggressive capabilities, such as the ability to move 
in clusters. In order for EMT to occur, there must be disruption of cell-cell adhesion 
(mediated by E-cadherin), cell-matrix adhesion, normal cell polarity, and the cell 
cytoskeleton. The genetic transition from epithelial to mesenchymal is triggered by the 
following transcriptional regulators: Snail1 (SNAI1), SNAI2, zinc-finger E-box-binding 
homeobox 1 (ZEB1), ZEB2, Twist, and E12/E47. The overall process is controlled by 
transforming growth factor-β (TGF-β), a multifunctional cytokine. Additional regulators 
include hypoxia, growth factors, metabolic changes, and immune response (Roche, 
2018). 
The miRNA-200 family consists of five members: miRNA-200a, miRNA-200b, 
miRNA-200c, miRNA-141, and miRNA-429. It was found that the miRNA-200 family 
and miRNA-205 were underexpressed in cells during the process of EMT in which TGF-
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β was used as the initiator (Gregory et al., 2008). In addition, enforced expression of the 
miRNA-200 family inhibited EMT. The mechanism by which these miRNAs prevent 
EMT is through the suppression of the transcription repressors for E-cadherin. If the 
transcription repressors are silenced, E-cadherin continues to be produced. As a result, 
the cell does not undergo EMT but can actually undergo the reverse process—
mesenchymal to epithelial transition (MET). The observation that these miRNAs were 
lost in breast cancer could explain the progression of tumors in these cases  (Gregory et 
al., 2008).  
The transcription factor p53 has also been shown to play a role in EMT through 
the direct activation of miRNA-200c. When p53 is downregulated in cancer, this leads to 
reduced production of miRNA-200c and a subsequent increase in stem cell production 
(Chang et al., 2011). Furthermore, p53 plays a role in repressing the expression of ZEB1 
and ZEB2, transcription factors that promote EMT. This is accomplished by means of the 
p53-mediated upregulation of miRNAs that repress ZEB1/2 expression (miRNA-200 and 
miRNA-192 families) (Kim et al., 2011). 
The downregulation of two other important miRNAs (miRNA-203 and miRNA-
212) is implicated in promoting EMT and giving tumorigenic cells metastatic or invasive 
potential. In highly metastatic breast cancer cells, it was determined that miRNA-203 was 
epigenetically downregulated (Ding, Park, McCauley, & Wang, 2013). There is a 
reciprocal repressive or double-negative feedback mechanism between SNAI2 and 
miRNA-203. This balance is shifted toward SNAI2 when TGF-β, a factor that promotes 
EMT, further induces SNAI2 to repress miRNA-203. If miRNA-203 is replete, SNAI2 is 
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repressed, yielding the inhibition of invasive or metastatic potential (Ding et al., 2013). 
Likewise, miRNA-212 has been studied in colorectal cancer (Meng et al., 2013). The 
compound manganese superoxide dismutase was involved in promoting factors that 
support EMT, which is downregulated by miRNA-212 under physiological conditions. 
However, downregulation of miRNA-212 by genetic or epigenetic mechanisms allowed 
for the expression of manganese superoxide dismutase in colorectal cancer, leading to 
more aggressive tumors and a worse prognosis in patients. When miRNA-212 was 
restored, the EMT process was blocked (Meng et al., 2013).  
 
Inducing Sustained Angiogenesis 
 Cancer is inherently linked to increased vascularity to provide oxygen to the 
growing tumor cells. Angiogenesis is an essential process that occurs during 
embryogenesis and is controlled by diverse factors. Of central importance in regulation of 
this process is vascular endothelial growth factor (VEGF). The initiation of growth and 
the maturation of new vessels depend primarily on the signaling induced by this growth 
factor. VEGF can also induce the production of the anti-apoptotic protein Bcl-2, and in 
this way it can prevent the death of cells in hypoxic conditions, in addition to producing 
new blood vessels to relieve hypoxic conditions. It would follow that levels of oxygen are 
the primary regulator of VEGF expression. This is accomplished through hypoxia-
inducible factor 1α (HIF-1α), which is released under hypoxic conditions (Ferrara, 2008). 
There are three known miRNAs that serve to protect against physiological tumor 
angiogenesis: miRNA-20b, miRNA-519c, and miRNA-107. miRNA-20b is regulated by 
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conditions of oxygen saturation. When miRNA-20b is inhibited, the protein levels of 
HIF-1α and VEGF increase. Because a reciprocal regulation mechanism exists in this 
system as well, the expression of HIF-1α directly inhibits miRNA-20b (Lei et al., 2009). 
HIF-1α is also regulated by miRNA-519c through the direct binding of the miRNA onto 
HIF-1α mRNA. If miRNA-519c is overexpressed, there is a significant decrease in HIF-
1α and a subsequent reduction in tumor angiogenesis (Cha et al., 2010). Finally, miRNA-
107 is involved in preventing angiogenesis through a role mediated by p53. As a 
transcription factor, p53 upregulates miRNA-107 to decrease hypoxia signaling. In colon 
cancer, it was found that miRNA-107 suppresses HIF-1β, and overexpression of miRNA-
107 can suppress tumor angiogenesis and VEGF expression (Yamakuchi et al., 2010). In 
summary, downregulation of any of these miRNAs can contribute to the potential for 
angiogenesis in tumorigenic cells, and when overexpressed, these miRNAs can be used 
as potent inhibitors of tumor progression.  
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REPLETION OF DOWNREGULATED miRNAs IN CANCER MODELS 
 
This section provides an overview of current efforts in preclinical models for 
miRNA replacement therapy. Although the studies presented in this section refer to 
targeting a specific gene, the regulation and downstream effects of miRNAs are diverse 
because of the fact that each miRNA regulates many genes. In addition, there is a large 
genetic diversity in tumor cells as previously discussed. This is further complicated by 
the fact that there is a considerable amount of redundancy within miRNAs and their 
targets. Families of miRNAs often have redundant functionality; thus, there is often no 
loss of function unless a whole family of miRNAs is downregulated (Alvarez-Saavedra & 
Horvitz, 2010). Different miRNAs can also target and repress different sections of the 
same mRNA (Tsang, Ebert, & van Oudenaarden, 2010). Finally, single miRNAs can 
target many genes, and when any one miRNA is downregulated, there are diverse 
implications for the entire system.  
 
Potential Target miRNAs Downregulated by Cancer  
 Based on miRNA expression profiles in cancers studied by Lu and colleagues 
(2005), downregulation of distinct miRNAs has been linked to various cancers. The top 
ten miRNAs downregulated in specific cancers are compiled in Table 1. 
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Table 1. Downregulated miRNAs Linked to Cancers by Systema 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aSummary of the top 10 miRNAs that are downregulated in cancers classified by their system. Poorly differentiated ovarian tumor has 
only 7 downregulated miRNAs of significance. let = lethal; miR = microRNA; miRNA = microRNA. Based on data collected by (Lu 
et al., 2005) and analyzed and compiled by (Cohen, Burgos-Aceves, & Smith, 2018). 
bT/N: tumor versus normal tissue. 
cPDT/T: poorly differentiated tumor (tumors that are more abnormal; i.e., tumors that have less features similar to normal tissue of the 
system and are associated with higher tumor grades) versus tumor.  
Breast 
(T/N)b 
Lung 
(T/N) 
Kidney 
(T/N) 
Colon 
(T/N) 
Prostate 
(T/N) 
Uterus 
(T/N) 
Breast 
(PDT/T)c 
Lung 
(PDT/T) 
Ovary 
(PDT/T) 
miR-199b miR-1 miR-194 miR-1 miR-1 miR-1 miR-29c miR-29c miR-33 
miR-99a miR-33 miR-215 miR-213 miR-33 miR-126 miR-33 miR-221 miR-210 
miR-130a miR-99a miR-124a miR-195 miR-144 miR-195 miR-221 miR-182 miR-15a 
miR-100 miR-126 miR-204 miR-125b miR-213 miR-140 miR-15a miR-214 miR-150 
miR-150 miR-144 miR-22 miR-96 miR-206 miR-213 miR-152 miR-148b miR-148b 
miR-195 miR-195 miR-199a miR-99a miR-150 miR-154 miR-148b miR-181b miR-181a 
let-7b miR-154 miR-199a let-7a miR-142-3p miR-182 miR-193 miR-199a miR-149 
miR-154 miR-196a miR-186 miR-30b miR-24 miR-214 miR-214 miR-181a 
 
miR-196a miR-130a miR-191 miR-153 miR-126 miR-10b miR-29a miR-15a 
 
miR-126 miR-152 miR-99a miR-19b miR-199b miR-150 miR-187 miR-187 
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Although the expression of these miRNAs has been shown to be downregulated in 
these cancers (Table 1), repletion of any miRNA in particular is not certain to reverse or 
inhibit the oncogenic phenotype. This is due to differing endogenous effects, which have 
not been fully elucidated for all of the listed miRNAs. Therefore, studies have focused on 
repletion of miRNA expression for those candidates that have been studied and proved to 
support a tumor-suppressive function. In particular, some miRNAs have been identified 
as being master regulators of a variety of tumor-suppressive functions. In these cases, 
multiple oncogenic processes can be impeded by the repletion of a single miRNA or 
miRNA family. Many of these studies have shown potential to slow or reverse the 
processes involved with oncogenesis in vivo or in tumor cell models.  
 
Overview of Preclinical Models for miRNA Replacement Therapy 
 From the discovery of miRNA in 1993 (Lee, Feinbaum, & Ambros, 1993), the 
field of research in miRNA has blossomed. Over 2500 human miRNAs have been 
identified (Kozomara & Griffiths-Jones, 2011), and the downregulation of many of these 
miRNAs has been linked to cancer. Table 2 presents an overview of candidate miRNAs 
that have demonstrated anticancer effects in preclinical models. In all of these cases, the 
miRNA was identified as being downregulated in the system under investigation. The 
studies referenced in Table 2 were performed either in vivo or in a cell culture model, 
with the miRNA listed in the first column being used by different experimental methods 
(some of which are described in the next section) to replenish the downregulated miRNA 
in that system. Thus, these studies provide important foundations for future developments 
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in miRNA replacement therapy as it moves toward trials in nonhuman primates and 
humans and eventually toward use as a molecular targeted cancer therapy in the clinic. 
Table 2 was partially compiled from the work of Nayer, Mahyar, Duijf, and 
Behzad (2018) and supplemented with 73 additional studies to provide a more thorough 
survey of ongoing efforts in this field. Nevertheless, even with these additions, this table 
is not a comprehensive survey of all the systems or tissues in which miRNA replacement 
has been evaluated. Rather, the intention of this table is to provide a general overview of 
candidate miRNAs that have been studied to date with examples from selected systems. 
Although the main targets that were found to be repressed in these studies are indicated, it 
is important to note that the miRNAs have a wide range of other targets as well. 
However, each specified target has a demonstrated link to oncogenesis involving one of 
the mechanisms described in the previous sections. The studies referenced in Table 2 
have been ordered numerically and compiled independently in the Appendix.  
 
Table 2. Survey of Preclinical Studies in miRNA Replacement Therapya  
miRNA  System/Tissue Target Study 
Let‐7 
Liver C‐myc, p16 1 
Lung KRAS 2 
Colon RAS, C‐myc 3 
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Table 2 (continued). Survey of Preclinical Studies in miRNA Replacement 
Therapya 
miRNA  System/Tissue Target Study 
Let-7 
Laryngeal RAS, C‐myc 4 
Gastric PKM2 5 
Let‐7, 34a Lung KRAS, P53 6, 7 
7 
Adrenal Raf-1 8 
CNS OGT 9 
CNS EGFR 10 
10b Uterine HOXB3 11 
16 
Lung VEGF 12 
Prostate CDK1, CDK2 13 
26a Breast MTDH 14 
27a Breast MDR‐1 15 
29 Liver Bcl‐2, Mcl‐1 16 
29b 
Blood SP1, CDK6, KIT 17 
Blood HDAC 18 
34a                                                                                              
Lung Bcl‐2 19, 20 
Pancreas Bcl‐2 21 
Gastric Bcl‐2 22 
CNS Bcl‐2, MMP2 23 
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Table 2 (continued). Survey of Preclinical Studies in miRNA Replacement 
Therapya 
miRNA  System/Tissue Target Study 
Colon E2F, P53 24 
34a 
Prostate Bcl‐2, CD44, SIRT1 25 
Melanoma MAPK 26 
Bone Notch1/ROCK1-PTEN-Akt-GSK-3β 27 
Breast SIRT1 28 
Liver C-myc 29 
99a Renal mTOR 30 
100 Bladder mTOR 31 
101 
Liver Mcl‐1 32 
Liver NLK, EZH2, Mcl‐1, STMN1, Rab5A 33 
Liver EZH2, COX2, STMN1, ROCK2 34 
107 Head & neck PKCε, CDK6, HIF1-β, Sox2 35 
122 
Liver Bcl-2 36 
Breast IGF-1R 37 
Liver ADAM10, SRF, IGF‐1R 38 
124 Colon PTB1 39 
125a-5p 
Breast HER2 40 
Gastric ERBB2 41 
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Table 2 (continued). Survey of Preclinical Studies in miRNA Replacement 
Therapya 
miRNA  System/Tissue Target Study 
125a-5p 
Colon Bcl-2, Bcl-2L12, Mcl-1 42 
CNS TAZ 43 
Prostate NAIF1, Caspase 3 44 
126 Gastric Crk 45 
128 Prostate BMI-1 46 
133b Gastric FBN1 47 
133‐b Lung Mcl‐1 48 
135a CNS STAT6, SMAD5, BMPR2 49 
137, 124 CNS CDK‐6 50 
143 Bone MMP13 51 
143, 145 Colon ERK‐5 52 
144 Liver EGFR, Src/Akt 53 
145, 33a Colon C‐myc, ERK‐5, Pim‐1 54 
145 
Colon STAT‐1, YES 55 
Lung, CNS Oct4, Sox2 56 
Gastric Ets1 57 
Lung Oct4/Sox2/Fascin1, Tcf4, Wnt5a  58 
Colon p70S6K1 (VEGF/HIF-1), IRS-1 59, 60 
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Table 2 (continued). Survey of Preclinical Studies in miRNA Replacement 
Therapya 
miRNA  System/Tissue Target Study 
145 
Liver IRS-1, IRS-2, IGF-1R 61 
Breast Fascin-1, C-myc, SMAD2/3, IGF-1R, ER-α 62, 63 
146a Liver EGFR, ERK1/2, STAT5 64 
146b CNS EGFR, NF-κB, SMAD4 65 
148a Breast Bcl-2 66 
148a, 152 Breast IGF-IR, IRS1 67 
150 Pancreas MUC4 68 
182 CNS Bcl-2L12, c-Met, HIF2-α 69 
185 Liver RHEB, RICTOR, AKT1 70 
185-3p, 
324-3p 
Nasopharyngeal SMAD7 71 
193a-3p Lung KRAS 72 
187 Colon CD276 73 
195 Liver ROCK2, VEGF 74 
200c 
Lung  ZEB1 75 
Liver ZEB1, ZEB2 76 
Ovarian TUBB3 77 
200b/c Liver SUZ12/ROCK2  78 
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Table 2 (continued). Survey of Preclinical Studies in miRNA Replacement 
Therapya 
miRNA  System/Tissue Target Study 
203 Breast  SNAI2 79 
203 Bladder Bcl‐2 80 
206 Liver cMET, Cyclin D1, CDK6 81 
302 Uterine Cyclin D1, CDK1 82 
320 Lung Bcl-2, Bax, Caspase 3 83 
326 Breast MRP‐1/ABCC1 84 
340 Liver JAK1/STAT3 85 
372 Head & Neck p62 86 
375 
Liver AEG-1, ATG7 87 
Esophageal LDHB, MTDH 88 
Head & Neck LDHB 89 
378 Gastric MAPK-1 90 
382 Lung SETD8 91 
424 Blood BCR-ABL 92 
449 Prostate Cyclin D1, HDAC1 93 
451 Breast MDR‐1 94 
451 CNS Bcl‐2, MMP‐2, MMP‐9, Akt1, Cyclin D1 95 
486 Lung IGF-1, IGF-1R, PIK3R1 96 
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Table 2 (continued). Survey of Preclinical Studies in miRNA Replacement 
Therapya 
miRNA  System/Tissue Target Study 
491 Ovarian Bcl-XL, EGFR  97 
495 Colon FAM83D  98 
508-5p CNS GPNMB 99 
520h Pancreas ABCG2 100 
542-3p Breast p53, Survivin 101 
603 Breast EF2K 102 
885-3p Colon Smad1/5/8, ID-1 103 
1258 Breast Heparanase 104 
 
aPartially compiled with studies from (Nayer, Mahyar, Duijf, & Behzad, 2018) and supplemented 
with 73 additional studies (Appendix) to provide a more complete overview of current efforts in the 
development of miRNA replacement therapy. CNS = central nervous system; miRNA = 
microRNA.  
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DEVELOPMENT OF miRNA THERAPEUTICS IN CANCER 
 
As presented in the previous section, there are a great diversity of candidates and 
encouraging results from preclinical studies performed in miRNA replacement. However, 
the many barriers toward translation of these encouraging preclinical results to the clinic 
have led to a slowing down of further development in this field. To date, there are only 
two completed phase I studies that have attempted to administer miRNA replacement 
therapeutics in an oncologic clinical trial (Beg et al., 2017; van Zandwijk et al., 2017). 
This section discusses the major hurdles in the pharmacological development of miRNA 
replacement therapies. It also evaluates the published results of the past two clinical trials 
and discusses the factors that have contributed to the lack of positive results.  
 
Challenges and Strategies in the Use of miRNAs as Therapeutic Agents 
Successful delivery of miRNAs to cancerous tissue is one of the greatest hurdles 
toward the clinical application of miRNA replacement therapy. As illustrated in Figure 5, 
miRNA replacement therapy can be divided into two subcategories of strategies: the use 
of miRNA mimics and the use of DNA plasmids to express miRNAs. Of the in vivo 
studies previously described, delivery was most often accomplished by viral vectors, 
liposomal transfection, or direct injection into the tumor site. Intratumoral injections are 
not widely practical in the clinic because of the small fraction of cases in which the tumor 
site is easily accessible and not metastasized. Therefore, the delivery options with the 
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best potential for translation to the clinic are lipid vesicles, dendrimers, gold 
nanoparticles, polymeric nanoparticles, and viral vectors. 
 
 
Figure 5. Strategies in miRNA replacement therapy. miRNA replacement therapy is 
executed through the use of miRNA mimics or the use of DNA plasmids that express 
miRNA. There are five broad categories for delivery methods: lipid vesicles, dendrimers, 
gold nanoparticles, polymeric nanoparticles, and viral vectors. BamH 1 = Bacillus 
amyloliquefaciens H 1; CMV = cytomegalovirus; miRNA = microRNA; mRNA = 
messenger RNA; RISC = RNA-induced silencing complex; Sv40 = simian virus 40. 
Figure taken from (Hosseinahli, Aghapour, Duijf, & Baradaran, 2018). 
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 Viral vectors have numerous issues preventing their successful use, including 
poor infectivity of target tissue, and these hurdles have been subjected to extensive 
research in the field of gene therapy. In addition, viral vectors generally involve a DNA 
vector and endogenous processing for maturation of the final product. Because many 
miRNA biogenic processes are impaired in cancer, this method of miRNA delivery is not 
likely to lead to successful clinical application (Trang et al., 2011). Thus, of the 
remaining nonviral methods of delivery, lipid vesicles and polymeric nanoparticles are 
the most important to examine 
 Endogenous extracellular or circulating miRNA is stable in peripheral blood. 
Although, in general, RNA is very unstable and subject to quick degradation by 
nucleases, miRNAs are immune to this to a certain extent. This is because the miRNAs 
travel in exosomes or microvesicles and associate with Argonaute proteins. It has been 
hypothesized that their stability is due to the fact that the circulating miRNAs are 
contained in the lipid membrane of dead cells (Turchinovich, Weiz, Langheinz, & 
Burwinkel, 2011). In an attempt to mimic this endogenous stability of miRNAs in 
plasma, the use of lipid vesicles is among the most popular methods of introducing 
miRNA into systems in preclinical models.  
 The miRNA-based therapeutic MRX34, an miRNA-34 mimic delivered in a 
liposomal nanoparticle, deserves special recognition as the first in its class to enter 
clinical testing. MRX34 uses patented nanoparticles in a technology given the trade name 
SMARTICLES® (Kelnar, Peltier, Leatherbury, Stoudemire, & Bader, 2014). This 
delivery vesicle consists of four types of lipids, some found endogenously in eukaryotic 
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cell membranes, with differing acidic and basic characteristics. The liposome is cationic 
during manufacturing to stabilize the oligonucleotide, but it can modify its pH 
physiologically to become anionic in the optimal range to facilitate entry to the target cell 
membranes (Tolcher et al., 2014). In animal models of liver tumors, this liposomal 
systemic delivery was found to cause regression of the cancer with no activation of 
immune response or toxic side effects (Daige et al., 2014). Thus, this delivery method 
showed great promise, and the FDA approved this investigational new drug for testing in 
humans.  
 Another method that showed success in preclinical models is targeted bacterial-
derived nanoparticles. This alternate delivery method was investigated because of certain 
key limitations in liposome drug delivery; namely, drug leakage and reduced potency. 
The pharmacological agent is able to be encapsulated in these nanoparticles, called 
minicells, which are derived from intentionally induced improper bacterial cell division. 
Furthermore, these minicells can be targeted to the site of interest through conjugation of 
the outer surface with antibodies (MacDiarmid et al., 2007). For example, antibodies to 
the epidermal growth factor receptor (EGFR) can be used to target the delivery to tumor 
cells because these receptors are overexpressed in cancer (Nicholson, Gee, & Harper, 
2001). This method, with the trade name EnGeneIC Dream Vector (EDV)TM nanocells, 
was used to deliver an miRNA-16 mimic to an animal model of malignant pleural 
mesothelioma. The results of this study showed tumor regression and specific targeting to 
cancerous cells but not normal mesothelial cells (Reid et al., 2013). Based on the 
favorable results of this study, a phase I clinical trial was initiated.  
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Clinical Trials in miRNA Replacement in Cancer 
The two clinical trials initiated in miRNA cancer therapeutics use miRNA mimics 
for repletion of two key candidates, miRNA-34a and miRNA-15/16. Both of these 
miRNA families are master regulators of tumor suppressor activity. They serve to 
promote a wide range of anti-oncogenic functions through the targeting of diverse genes. 
If these genes are overexpressed, they contribute to oncogenesis by multiple mechanisms 
(Figure 6). The efficacy and safety of these clinical trials are discussed in this section.   
MRX34: A Mimic of miRNA-34 
In many cancers, it has been found that miRNA-34 is downregulated. As 
discussed previously, miRNA-34 shares a regulatory axis with the tumor suppressor p53 
(Chang, Wentzel, et al., 2007) and is known to control more than 30 oncogenes (some of 
which are listed in Figure 6). A phase I clinical trial was conducted on patients with 
advanced solid tumors refractory to standard treatment (Beg et al., 2017). Over the 17 
weeks of the trial, 47 patients were given at least one dose of the medication, and over 
60% of the treated patients discontinued the study because of disease progression. Of the 
41 patients who were able to be evaluated for tumor progression, one patient partially 
responded to the treatment, 6 patients were stabilized, and 32 patients progressed in their 
disease. Infusion-related adverse effects were a significant concern for this study, as they 
interfered with the administration of the medication and thus did not allow for continuous 
and consistent dosing. Although direct cause could not be determined, it was postulated 
that the infusion-related adverse effects were related to the liposomal delivery method. 
The authors attributed the majority of the adverse effects to general immune reactions 
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that occur in response to dsRNA. Although there was response in some patients, this 
study was terminated prematurely because of the number of adverse events that were 
classified as serious (Beg et al., 2017).  
 
 
Figure 6. Molecular targets of miRNAs in clinical development. (A) miRNA-34 and 
(B) miRNA-15/16 serve tumor suppressor functions in many oncogenic pathways, and 
they are significantly downregulated in many cancers. This figure provides examples of 
the oncogenes and the resulting tumorigenic properties that these miRNAs inhibit. BCL = 
B-cell lymphoma; BMI1 = B-cell-specific Mo-MLV insertion site-1; CDC25A = cell 
division cycle 25A; CDK = cyclin-dependent kinase; LDHA = lactate dehydrogenase A; 
miR = microRNA; miRNA = microRNA; PDL = programmed death ligand; TERT = 
telomerase reverse transcriptase; VEGF = vascular endothelial growth factor. Figure 
modified from (Ivkovic, Voss, Cornella, & Ceder, 2017). 
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TargomiRs: A Mimic of miRNA-16 
The loss of miRNA-15/16 is noted in many human malignancies. After promising 
results in the preclinical use of minicells with miRNA-16 mimics targeted to EGFR to 
treat mesothelioma (Reid et al., 2013), a clinical trial was conducted with the same 
therapy. In this phase I study, 27 patients with malignant pleural mesothelioma and 
tumors significantly expressing EGFR were enrolled (van Zandwijk et al., 2017). More 
than half of the patients reported the adverse event of non-cardiac chest pain that the 
investigators believed was related to accumulation of the drug around the leaky tumor 
vasculature. Nevertheless, the investigators found significant stabilization of disease 
progression and even a partial response that lasted for 32 weeks in one patient. These 
results are encouraging for future trials, but no significant conclusions can be drawn 
because of the small sample size. In addition, the maximum tolerated dose was quite low 
compared with the minimum effective dose that was found in murine studies. The 
investigators postulated that the serious inflammation-related adverse events, which 
caused only a low dose to be tolerated, were due to the minicell carrier method and not 
the miRNA mimic. These results encourage future development with this candidate, 
possibly with different routes of administration or delivery methods, and phase II trials 
are likely to take place with some modifications to the candidate (van Zandwijk et al., 
2017).  
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FUTURE DIRECTIONS AND CONCLUSIONS 
 
The Potential for miRNA in Gene Silencing 
Treating disease through knockdown of specific genes is an attractive concept that 
has been under speculation with the discovery of RNA interference. Accomplishing 
knockdown by the use of synthetically developed miRNA is one technique to achieve this 
goal. This concept is beginning to be investigated in cancer. For example, one study 
aimed to downregulate heparanase, an enzyme involved in promoting metastasis, by the 
application of an artificially created miRNA (Liu et al., 2012). The investigators designed 
an miRNA based on miRNA-155 and modified the key sequence to target heparanase. 
The artificial miRNA showed effective inhibition of heparanase mRNA and knockdown 
of the resulting protein, decreasing metastasis both in vitro and in vivo. In addition, an 
important benefit of this method is that tissue-specific expression can be achieved using 
special RNA polymerase II promoters (Liu et al., 2012). 
Although studies such as the one by X. Liu and colleagues (2012) showed proof 
of concept, it is not clear whether this method of RNA interference will be the subject of 
future development. The artificial miRNA modified from miRNA-155 has shown 
promise in targeted knockdown of one enzyme in cancerous tissue, and its use could 
theoretically provide the potential benefit of being able to target and knock down many 
different oncogenic genes with one sequence. However, in practical use, this benefit 
versus the benefits of other gene therapy methods has not yet been established. 
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Furthermore, translating this method to clinical use will face the same setbacks as the rest 
of the field of gene therapy because of the lack of development of well-tolerated and 
efficacious delivery systems. 
 
Conclusions 
 There is currently an unmet need in targeted cancer therapies. However, with 
better understanding of the genome of cancers, the molecular mechanisms of 
oncogenesis, and gene therapy, much progress is being made in this arena. The discovery 
of the link between cancer and miRNA has fueled a new field of research and 
development. Specifically, progress has been made in uncovering how mechanisms of 
oncogenesis can lead to changes in the regulation of miRNA and how the downregulation 
of miRNA contributes to the formation of cancer. These reciprocal mechanisms are 
emerging as a hallmark of cancer and provide an excellent target for therapy.  
The use of miRNAs as therapeutic agents has garnered considerable interest as 
techniques in gene therapy become more refined. The concept of repletion of miRNA 
expression when it is downregulated in cancer has shown much progress in preclinical 
studies. miRNA replacement therapy is an attractive concept because it attempts to treat 
cancer through restoration of an endogenous pathway that has gone awry, and as a result, 
it may possibly lead to less toxic side effects than more traditional cancer-killing 
therapeutic concepts.  
This thesis has reviewed the mechanisms underlying miRNA and its links to 
cancer and provided an overview of in vitro and in vivo studies working to remedy the 
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imbalance caused by oncogenic processes. In particular, this thesis has given examples of 
over 100 studies in which miRNA replacement therapy has exhibited extremely 
efficacious results in preclinical models of cancer. There are numerous examples of 
candidate miRNAs that show the potential to silence many different targets in diverse 
systems of cancer. Unfortunately, with only two clinical trials completed in this field, 
these successes at the bench have not yet been translated into therapeutic successes in 
patients. Nevertheless, there are several clinical trials in progress in cancer and other 
diseases.  
The greatest impediment to the clinical use of miRNA is the availability of 
effective delivery systems. However, incredibly diverse techniques for nonviral delivery 
of pharmacological agents are beginning to be introduced. The promising results seen in 
the TargomiRs trial, which used nanoparticles to directly target the cancer site, provide 
hope for the future, especially with the continued development in phase II clinical trials. 
With a small amount of refinement, miRNA therapeutic agents hold boundless potential 
as a safer and more efficacious treatment in cancer. 
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